

**Anti-IL-4Ra / CD124 Reference Antibody (Manfidokimab)
Recombinant Antibody
Catalog # APR10719****Specification**

Anti-IL-4Ra / CD124 Reference Antibody (Manfidokimab) - Product Information

Application	FC, E, FTA
Primary Accession	P24394
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG4SP
Calculated MW	143.86 KDa

Anti-IL-4Ra / CD124 Reference Antibody (Manfidokimab) - Additional Information**Target/Specificity**

IL-4Ra / CD124

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-IL-4Ra / CD124 Reference Antibody (Manfidokimab) - Protein Information**Name** IL4R**Synonyms** IL4RA**Function**

Receptor for both interleukin 4 and interleukin 13 (PubMed:17030238). Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2.

Cellular Location

Cell membrane; Single-pass type I membrane protein

Tissue Location


Isoform 1 and isoform 2 are highly expressed in activated T-cells

Anti-IL-4Ra / CD124 Reference Antibody (Manfidokimab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-IL-4Ra / CD124 Reference Antibody (Manfidokimab) - Images



Anti-IL-4Ra / CD124 Reference Antibody (Manfidokimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-4Ra / CD124 Reference Antibody (Manfidokimab) is more than 99.14%, determined by SEC-HPLC.